BUY Dr. Reddy's Laboratories Limited — Ashish Bahety, Profitmart Securities
byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))22 Jun 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·23 Jun · yesterday
Dr. Reddy's Laboratories Limited announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.
NSE · Press Release·13 Jun · 2w ago
Dr. Reddy's Laboratories Ltd. has launched Bosutinib Tablets 400mg.
BSE · Company Update·13 Jun · 2w ago
Nothing found in this tip’s window yet.
1 advisor has an active short-term SELL call on this stock
Advisor consensus · adjacent horizon·15 Apr · 2mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.